BVCF Management, a healthcare investment company, led a $15m Series A financing round in Cellenkos, a biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders. "Cellenkos' innovative and transformative Treg cell therapy platform to address autoimmune and inflammatory disorders has the potential to significantly serve unmet patient needs. We are proud to lead the financing and support their groundbreaking efforts," Dr. Zhi Yang, BVCF Managing Partner.